ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,519,610 | -14.3% | 461,299 | -2.9% | 0.02% | -6.2% |
| Q2 2023 | $14,611,244 | +96843.0% | 475,317 | +13.6% | 0.02% | -15.8% |
| Q1 2023 | $15,072 | -7.2% | 418,306 | +1.7% | 0.02% | -13.6% |
| Q4 2022 | $16,248 | -99.9% | 411,142 | +6.4% | 0.02% | -4.3% |
| Q3 2022 | $15,520,000 | +7.1% | 386,253 | +12.0% | 0.02% | +9.5% |
| Q2 2022 | $14,494,000 | +34.0% | 344,778 | +24.2% | 0.02% | +50.0% |
| Q1 2022 | $10,816,000 | -4.0% | 277,607 | -1.8% | 0.01% | 0.0% |
| Q4 2021 | $11,264,000 | +14.4% | 282,663 | +3.7% | 0.01% | +7.7% |
| Q3 2021 | $9,848,000 | -16.9% | 272,502 | -5.8% | 0.01% | -18.8% |
| Q2 2021 | $11,857,000 | -8.4% | 289,256 | -2.5% | 0.02% | -11.1% |
| Q1 2021 | $12,947,000 | +165.7% | 296,803 | +204.8% | 0.02% | +157.1% |
| Q4 2020 | $4,873,000 | +50.9% | 97,361 | +26.8% | 0.01% | +40.0% |
| Q3 2020 | $3,230,000 | – | 76,769 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |